Beryl Drugs Limited (BOM:524606)
India · Delayed Price · Currency is INR 21.91
-0.99 (-4.32%)
At close: Jan 20, 2026
Beryl Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 191.97 | 211.46 | 267.3 | 268.71 | 146.04 | 140.93 | Upgrade |
| 191.97 | 211.46 | 267.3 | 268.71 | 146.04 | 140.93 | Upgrade | |
Revenue Growth (YoY) | -14.53% | -20.89% | -0.53% | 84.00% | 3.62% | 9.97% | Upgrade |
Cost of Revenue | 96.96 | 112.22 | 135.62 | 148.43 | 85.66 | 75.99 | Upgrade |
Gross Profit | 95.02 | 99.24 | 131.68 | 120.28 | 60.37 | 64.94 | Upgrade |
Selling, General & Admin | 23.71 | 22.58 | 19.69 | 17.3 | 13.46 | 12.08 | Upgrade |
Other Operating Expenses | 45.37 | 48.05 | 84.68 | 80.64 | 41.4 | 36.68 | Upgrade |
Operating Expenses | 85.47 | 85.47 | 117.24 | 106.18 | 65.72 | 61.49 | Upgrade |
Operating Income | 9.55 | 13.77 | 14.44 | 14.1 | -5.35 | 3.45 | Upgrade |
Interest Expense | -3.69 | -5.19 | -4.48 | -4.18 | -4.2 | -4.27 | Upgrade |
Interest & Investment Income | 0.19 | 0.19 | 0.21 | 0.12 | 0.14 | 0.17 | Upgrade |
Other Non Operating Income (Expenses) | -0.12 | -0.12 | -0.18 | -0.2 | 0 | -0.39 | Upgrade |
EBT Excluding Unusual Items | 5.92 | 8.66 | 9.99 | 9.84 | -9.41 | -1.04 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | 0.11 | - | - | - | Upgrade |
Other Unusual Items | - | - | - | - | -0.09 | 4.52 | Upgrade |
Pretax Income | 5.92 | 8.66 | 10.1 | 9.84 | -9.5 | 3.48 | Upgrade |
Income Tax Expense | 3.58 | 2.87 | 2.41 | 2.18 | -2.91 | 1.08 | Upgrade |
Net Income | 2.34 | 5.79 | 7.69 | 7.66 | -6.59 | 2.4 | Upgrade |
Net Income to Common | 2.34 | 5.79 | 7.69 | 7.66 | -6.59 | 2.4 | Upgrade |
Net Income Growth | -30.93% | -24.69% | 0.34% | - | - | 399.78% | Upgrade |
Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 5 | 5 | Upgrade |
Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 5 | 5 | Upgrade |
Shares Change (YoY) | -0.68% | - | - | - | -0.01% | 0.01% | Upgrade |
EPS (Basic) | 0.46 | 1.14 | 1.52 | 1.51 | -1.30 | 0.47 | Upgrade |
EPS (Diluted) | 0.46 | 1.14 | 1.52 | 1.51 | -1.30 | 0.47 | Upgrade |
EPS Growth | -30.64% | -24.78% | 0.36% | - | - | 422.22% | Upgrade |
Free Cash Flow | -11.9 | 4.52 | -5.31 | 8.28 | -8.84 | -13.33 | Upgrade |
Free Cash Flow Per Share | -2.36 | 0.89 | -1.05 | 1.63 | -1.74 | -2.63 | Upgrade |
Gross Margin | 49.49% | 46.93% | 49.26% | 44.76% | 41.34% | 46.08% | Upgrade |
Operating Margin | 4.97% | 6.51% | 5.40% | 5.25% | -3.66% | 2.45% | Upgrade |
Profit Margin | 1.22% | 2.74% | 2.88% | 2.85% | -4.51% | 1.70% | Upgrade |
Free Cash Flow Margin | -6.20% | 2.14% | -1.99% | 3.08% | -6.05% | -9.46% | Upgrade |
EBITDA | 23.56 | 26.23 | 26.44 | 22.25 | 5.52 | 16.18 | Upgrade |
EBITDA Margin | 12.27% | 12.40% | 9.89% | 8.28% | 3.78% | 11.48% | Upgrade |
D&A For EBITDA | 14.01 | 12.46 | 12 | 8.14 | 10.87 | 12.74 | Upgrade |
EBIT | 9.55 | 13.77 | 14.44 | 14.1 | -5.35 | 3.45 | Upgrade |
EBIT Margin | 4.97% | 6.51% | 5.40% | 5.25% | -3.66% | 2.45% | Upgrade |
Effective Tax Rate | 60.49% | 33.14% | 23.87% | 22.14% | - | 31.15% | Upgrade |
Revenue as Reported | 206.15 | 225.55 | 271.25 | 271.4 | 147.69 | 142.8 | Upgrade |
Advertising Expenses | - | 0.16 | 0.12 | 0.17 | 0.13 | 0.13 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.